Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06OZJ
|
|||
| Former ID |
DNC001245
|
|||
| Drug Name |
RWJ-67657
|
|||
| Synonyms |
215303-72-3; RWJ-67657; RWJ 67657; RWJ67657; 4-[4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1-ol; CHEMBL190333; 4-(4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl)but-3-yn-1-ol; 4-(4-Fluorophenyl)-2-(4-hydroxy-1-butynyl)-1-(3-Phenylpropyl)-5-(4-Pyridyl)imidazole; 4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridyl)imidazol-2-yl]but-3-yn-1-ol; 4-(4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl)-3-butyn-1-ol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Arthritis [ICD-11: FA20] | Phase 1 | [1] | |
| Therapeutic Class |
Analgesics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H24FN3O
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)CCCN2C(=NC(=C2C3=CC=NC=C3)C4=CC=C(C=C4)F)C#CCCO
|
|||
| InChI |
1S/C27H24FN3O/c28-24-13-11-22(12-14-24)26-27(23-15-17-29-18-16-23)31(25(30-26)10-4-5-20-32)19-6-9-21-7-2-1-3-8-21/h1-3,7-8,11-18,32H,5-6,9,19-20H2
|
|||
| InChIKey |
QSUSKMBNZQHHPA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 215303-72-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
3720130, 10038746, 14782797, 36057105, 57410202, 79140398, 103461888, 104137084, 111624293, 124950173, 125697878, 126671721, 129070177, 134340457, 135141704, 135685296, 135685297, 135685316, 135698854, 137275843, 140058336, 152344436, 162815368, 164233574, 164764920, 174560978, 180371708, 204360619, 223664282, 223798817, 226524969, 241376206, 249617731, 252156935, 252216243, 252543343
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J Pharmacol Exp Ther. 1999 Nov;291(2):680-7. | |||
| REF 2 | Monocyte intracellular cytokine production during human endotoxaemia with or without a second in vitro LPS challenge: effect of RWJ-67657, a p38 MAP-kinase inhibitor, on LPS-hyporesponsiveness. Clin Exp Immunol. 2002 Feb;127(2):337-43. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.